Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis

Phase 3CompletedNCT02093663

Shire107 enrolled

Overview

To assess clinical response to MMX mesalamine/mesalazine between a low and high dose in children and adolescents aged 5-17 years with mild to moderate Ulcerative Colitis (UC) or who are in remission.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

107

Conditions

Ulcerative Colitis

Interventions

MMX Mesalamine/Mesalazine (Low Dose)DRUG

Once daily, tablets - the amount depends on the participants weight; 900 milligram per day (mg/day) for participants weighing 18 kg to less than or equal to (\<=) 23 kilograms (kg); 1200 mg/day for participants weighing greater than (\>) 23 kg to \<= 35 kg; 1800 mg/day for participants weighing \> 35 kg to \<= 50 kg; 2400 mg/day for participants weighing \> 50 kg to \<= 90 kg.

MMX Mesalamine/Mesalazine (High Dose)DRUG

Once daily, tablets - the amount depends on the participants weight;1800 mg/day for participants weighing 18 kg to \<= 23 kg; 2400 mg/day for participants weighing \> 23 kg to \<= 35 kg; 3600 mg/day for participants weighing \> 35 kg to \<= 50 kg; 4800 mg/day for participants weighing \> 50 kg to \<= 90 kg.

Eligibility

Sex: ALLMin age: 5 YearsMax age: 17 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Ability to voluntarily provide written, signed, and dated (personally or via a legally authorized representative \[LAR\]) informed consent or assent as applicable to participate in the study. 2. Subject's parent/LAR demonstrates an understanding, ability, and willingness to fully comply with study procedures and restrictions. 3. Male and female children and adolescents aged 5-17 years, inclusive. 4. Body weight 18-90kg. 5. Male, or non-pregnant, non-lactating female who agrees to comply with any applicable contraceptive requirements of the protocol or females of non-childbearing potential. 6. Diagnosed with mild to moderate UC, established by sigmoidoscopy or colonoscopy with compatible histology. Screened subjects may also have an unconfirmed diagnosis of mild to moderate UC; however the diagnosis of mild to moderate UC must have been established by sigmoidoscopy or colonoscopy with compatible histology prior to baseline visit. 7. Subject is able to swallow the investigational product whole. Double-blind Acute Phase: 8. Partial UC-DAI score ≥2 (a combined rectal bleeding and stool frequency score ≥1 and PGA=1 or 2) at the Baseline Visit, for which 5-ASA would be used as part of normal treatment. 9. If the subject is on 5-ASA treatment prior to study entry, then the dose must be stable. Stable therapy is defined as no change in dose, or no initiation of 5-ASA, from the onset of the current acute flare through discontinuation of therapy (required at the Baseline Visit). Double-blind Maintenance Phase: 10. Partial UC-DAI ≤1 (rectal bleeding=0, stool frequency ≤1, and PGA=0) at the Baseline Visit. Exclusion Criteria: 1. Severe UC (defined by PGA=3). 2. Crohn's disease, bleeding disorders, active peptic ulcer disease, or UC known to be confined to the rectum (isolated rectal proctitis). 3. Asthma, only if known to be 5 ASA sensitive. 4. Positive stool culture for enteric pathogens (including Salmonella, Shigella, Yersinia, Aeromonas, Plesiomonas, or Campylobacter). Clostridium difficile toxin, ova, or parasites present. 5. Systemic or rectal corticosteroid use within 4 weeks prior to the Screening Visit. Topical, intranasal, or inhaled use is not exclusionary. 6. Immunomodulator (6-mercaptopurine, azathioprine) use within 6 weeks prior to the Screening Visit. 7. History of biologic (eg, anti-tumor necrosis factor agents, integrin receptor antagonists) use at any time. 8. Antibiotic use within 7 days prior to the Screening Visit. 9. Any anti-inflammatory drugs, not including 5-ASA treatment but including non-steroidal anti-inflammatory drugs such as aspirin, COX-2 inhibitors or ibuprofen, within 7 days prior to the Screening Visit unless used at over-the-counter levels for \<3 days. However, prophylactic use of a stable dose of aspirin up to 325mg/day for cardiac disease is permitted. 10. Prebiotic/probiotic use within 7 days prior to the Screening Visit. Yogurt products are permitted.

Locations (33)

Outcomes

Primary Outcomes

Number of Participants With Clinical Response During Double-Blind Acute Phase at Week 8

Clinical response was defined as partial ulcerative colitis disease activity index (UC-DAI) score \< or =1 with rectal bleeding = 0, stool frequency \< or =1, and physician's global assessment (PGA = 0). Number of participants with clinical response were reported.

Time frame: Week 8

Number of Participants With Clinical Response During Double-blind Maintenance Phase at Week 26

Clinical response was defined as partial UC-DAI \<=1 with (rectal bleeding = 0, stool frequency \< or =1, and PGA = 0). Number of participants who had maintained clinical response were reported.

Time frame: Week 26

Secondary Outcomes

Number of Participants With Clinical and Endoscopic Response During Double Blind Acute Phase at Week 8 Using Central Reading

Clinical and endoscopic response was defined as UC-DAI \<=2 with rectal bleeding = 0 and stool frequency \<=1, and PGA = 0, and with mucosal healing (endoscopy score \<=1) at least a 1 point reduction in endoscopy score from baseline based on central reading. Participants with missing data at week 8 were assumed not to had a clinical response. Participants who completed week 8 but did not have central reading endoscopies at both baseline and week 8 were excluded. Number of participants with clinical and endoscopic response were reported.

Time frame: Week 8

Number of Participants With Clinical and Endoscopic Response During Double Blind Acute Phase at Week 8 Using Local Reading

Clinical and endoscopic response was defined as UC-DAI \< or =2 with rectal bleeding = 0 and stool frequency \< or =1, and PGA = 0, and with mucosal healing (endoscopy score \< or =1) at least a 1 point reduction in endoscopy score from baseline based on local reading. Participants with missing data at week 8 were assumed not to had a clinical response. Participants who completed week 8 but did not have local reading endoscopies at both baseline and week 8 were excluded. Number of participants with clinical and endoscopic response were reported.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

University of Maryland Children's Hospital

Baltimore, Maryland, United States

John Hopkins

Baltimore, Maryland, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

Newton Wellesley Hospital

Newton, Massachusetts, United States

University of Minnesota Children's Hospital

Minneapolis, Minnesota, United States

Mayo Clinic Gastroenterology

Rochester, Minnesota, United States

Penn State Milton S. Hershey Medical Center

Hershey, Pennsylvania, United States

Texas Digestive Disease Consultants

Southlake, Texas, United States

Carilion Medical Center

Roanoke, Virginia, United States

University of Alberta Pediatric Gastroenterology & Nutrition

Edmonton, Alberta, Canada

...and 23 more locations